Skip to main content
Special Populations

GLP-1 & Fertility: What to Know

Updated October 21, 2026Special PopulationsPublished by Surfbound Health

If you decide to start

Compounded semaglutide $169/month · tirzepatide $219/month

One flat price at every prescribed dose. No membership fee. Medication and discreet shipping included if prescribed.

Pregnancy during weight-management treatment

Pregnancy can occur during weight-management treatment, including when periods have previously been irregular. GLP-1 medicines are not established fertility treatments. Discuss contraception and pregnancy plans before treatment.

How weight management affects female fertility

Obesity is associated with hormonal disruption (excess estrogen from fat tissue), insulin resistance affecting ovulation, and inflammation affecting egg quality and implantation. Weight management addresses some of these factors. Weight management may improve ovulation in some people with PCOS, but pregnancy is not guaranteed. Available evidence does not establish tirzepatide as a fertility treatment or cleanly separate medication effects from weight-loss effects.

The 2023 international PCOS guideline considers anti-obesity medicines for weight management when otherwise appropriate, but recommends their use specifically to improve reproductive outcomes only in research settings. That is a narrower recommendation than using these medicines for general weight management in PCOS.

Pregnancy and contraception safety

Tell your prescriber if you are pregnant, could become pregnant, are planning pregnancy, or are breastfeeding. Tirzepatide used for weight management should be stopped when pregnancy is recognized. Weight loss offers no benefit during pregnancy, and tirzepatide may harm the fetus. Contact your prescriber promptly if pregnancy occurs or is suspected.

If you use birth control pills, tirzepatide can reduce their effectiveness. The US prescribing information advises switching to a non-oral contraceptive or adding a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after every dose increase. Hormonal contraception that is not taken by mouth is not expected to be affected by tirzepatide’s effect on stomach emptying. The details are in our guide to GLP-1 treatment and birth control.

Planning pregnancy around GLP-1 treatment

Arrange a medication and pregnancy plan with your prescriber before trying to conceive. The stopping interval differs by medicine, and the US Zepbound label does not specify a preconception interval. The US semaglutide label advises stopping at least 2 months before planned pregnancy. UK guidance advises stopping tirzepatide at least 1 month beforehand. Your prescriber should individualize your plan rather than applying one interval to every GLP-1 medicine.

Use the transition period to establish nutrition and activity habits that support a healthy pregnancy, and continue folic acid or prenatal vitamin supplementation. Some prescribers may prefer a stable weight before stopping treatment, because active weight loss is not recommended during pregnancy.

Breastfeeding

A small study after one tirzepatide dose found very low or undetectable levels in breast milk. This does not establish safety for infants during ongoing treatment. Effects on infants and milk production remain uncertain. Discuss your treatment needs and breastfeeding with your prescriber before use. When you plan to restart after pregnancy, do not restart at a previous dose without a new clinical plan.

Male fertility considerations

Human fertility-outcome data for tirzepatide are limited. The approved-product label reports no effect on sperm morphology, mating, fertility or conception in male rats; that does not prove improved fertility or establish all human reproductive outcomes. Obesity is associated with hormonal disruption, increased scrotal temperature and oxidative stress, and weight loss is generally associated with improved testosterone levels and sperm parameters. Men actively trying to conceive should discuss treatment with their prescriber and, where relevant, a reproductive specialist.

Ready to take the next step?

Discuss family planning with your provider

Frequently asked questions

GLP-1 medicines are not established fertility treatments. Weight management may improve ovulation in some people with PCOS, but pregnancy is not guaranteed. Available evidence does not establish tirzepatide as a fertility treatment or cleanly separate medication effects from weight-loss effects.

It depends on the medicine. The US Zepbound label does not specify a preconception stopping interval. The US semaglutide label advises stopping at least 2 months before a planned pregnancy, and UK guidance advises stopping tirzepatide at least 1 month beforehand. Arrange an individualized medication and pregnancy plan with your prescriber before trying to conceive.

Stop tirzepatide used for weight management when pregnancy is recognized and contact your prescriber and obstetric clinician promptly. Human pregnancy data, especially for tirzepatide, remain insufficient to establish safety or predict an individual outcome.

A small study after one tirzepatide dose found very low or undetectable levels in breast milk, but this does not establish safety for infants during ongoing treatment, and effects on infants and milk production remain uncertain. Discuss your treatment needs and breastfeeding with your prescriber before use. Do not restart at a previous dose without a new clinical plan.

Sources

This guide is published by Surfbound Health (Organization). It is educational content, not medical advice, and it does not replace an individual evaluation by a licensed provider.

Sources

Want more evidence-based health research from Surfbound?

Add Surfbound as a Preferred Source on Google